Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K.'s Cost Regulator Wants Allergan To Compare Ozurdex With Avastin In Macular Edema

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE says it is "minded" to reject Allergan's Ozurdex but might be persuaded it is stacks up well against off-label Avastin use.

You may also be interested in...



NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day

Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.

NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day

Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.

U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal

NICE's preliminary rejection of Lucentis for macular edema paves the way for cheaper Avastin to swallow up most of the U.K. market.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel